Andere talen CStone Pharmaceuticals

Aandelen

2616

KYG2588M1006

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:09 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,9 ^HKD	-2,17%		0,00%	-60,35%

24/04	Cstone Pharmaceuticals boekt lager verlies over 2023, aandelen stijgen met bijna 5%	MT
23/04	CStone Pharmaceuticals rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	24/04
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	23/04
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	09/04
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	09/04
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved	15/03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer	15/03
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%	04/03
CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore	22/12
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million	21/12
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.	21/12
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%	13/12
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma	11/12
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%	08/12
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma	08/12
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	02/11
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China	01/11
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China	01/11
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma	31-10-23
China Approves CStone's Lymphoma Medication	31-10-23
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug	24-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CStone Pharmaceuticals

Aandelen

2616

KYG2588M1006

Andere talen

Filters